164 related articles for article (PubMed ID: 37553047)
1. Advances in molecular mechanism of HPV16 E5 oncoprotein carcinogenesis.
Chen B; Zhao L; Yang R; Xu T
Arch Biochem Biophys; 2023 Sep; 745():109716. PubMed ID: 37553047
[TBL] [Abstract][Full Text] [Related]
2. Cellular Functions of HPV16 E5 Oncoprotein during Oncogenic Transformation.
Gutierrez-Xicotencatl L; Pedroza-Saavedra A; Chihu-Amparan L; Salazar-Piña A; Maldonado-Gama M; Esquivel-Guadarrama F
Mol Cancer Res; 2021 Feb; 19(2):167-179. PubMed ID: 33106372
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus 16/18 E5 promotes cervical cancer cell proliferation, migration and invasion in vitro and accelerates tumor growth in vivo.
Liao S; Deng D; Zhang W; Hu X; Wang W; Wang H; Lu Y; Wang S; Meng L; Ma D
Oncol Rep; 2013 Jan; 29(1):95-102. PubMed ID: 23128977
[TBL] [Abstract][Full Text] [Related]
5. Glycogene expression profiles from a HaCaT cell line stably transfected with HPV16 E5 oncogene.
Cisneros-Ramírez D; Martínez-Laguna Y; Martínez-Morales P; Aguilar-Lemarroy A; Jave-Suárez LF; Santos-López G; Reyes-Leyva J; Vallejo-Ruiz V
Mol Med Rep; 2020 Dec; 22(6):5444-5453. PubMed ID: 33174037
[TBL] [Abstract][Full Text] [Related]
6. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.
Ren S; Gaykalova DA; Guo T; Favorov AV; Fertig EJ; Tamayo P; Callejas-Valera JL; Allevato M; Gilardi M; Santos J; Fukusumi T; Sakai A; Ando M; Sadat S; Liu C; Xu G; Fisch KM; Wang Z; Molinolo AA; Gutkind JS; Ideker T; Koch WM; Califano JA
Oncogene; 2020 Oct; 39(40):6327-6339. PubMed ID: 32848210
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies.
Bhattacharjee R; Das SS; Biswal SS; Nath A; Das D; Basu A; Malik S; Kumar L; Kar S; Singh SK; Upadhye VJ; Iqbal D; Almojam S; Roychoudhury S; Ojha S; Ruokolainen J; Jha NK; Kesari KK
Crit Rev Oncol Hematol; 2022 Jun; 174():103675. PubMed ID: 35381343
[TBL] [Abstract][Full Text] [Related]
8. Repression of Memo1, a Novel Target of Human Papillomavirus Type 16 E7, Increases Cell Proliferation in Cervical Cancer Cells.
Trejo-Cerro O; Massimi P; Broniarczyk J; Myers M; Banks L
J Virol; 2022 Oct; 96(20):e0122922. PubMed ID: 36197110
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment.
Kim MK; Kim HS; Kim SH; Oh JM; Han JY; Lim JM; Juhnn YS; Song YS
Biochem Pharmacol; 2010 Dec; 80(12):1930-5. PubMed ID: 20643111
[TBL] [Abstract][Full Text] [Related]
10. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells.
Boulenouar S; Weyn C; Van Noppen M; Moussa Ali M; Favre M; Delvenne PO; Bex F; Noël A; Englert Y; Fontaine V
Carcinogenesis; 2010 Mar; 31(3):473-80. PubMed ID: 19917629
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus does not have a causal role in colorectal carcinogenesis.
Lorenzon L; Mazzetta F; Pilozzi E; Uggeri G; Torrisi MR; Ferri M; Ziparo V; French D
World J Gastroenterol; 2015 Jan; 21(1):342-50. PubMed ID: 25574110
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.
Cerasuolo A; Annunziata C; Tortora M; Starita N; Stellato G; Greggi S; Maglione MG; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML
Oncotarget; 2017 May; 8(21):34070-34081. PubMed ID: 28423662
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of HPV16 L2 gene in cervical cancers harboring episomal HPV16 genomes: influence of synonymous and non-coding region variations.
Mandal P; Bhattacharjee B; Das Ghosh D; Mondal NR; Roy Chowdhury R; Roy S; Sengupta S
PLoS One; 2013; 8(6):e65647. PubMed ID: 23762404
[TBL] [Abstract][Full Text] [Related]
14. ZER1 Contributes to the Carcinogenic Activity of High-Risk HPV E7 Proteins.
Nouel J; White EA
mBio; 2022 Dec; 13(6):e0203322. PubMed ID: 36346242
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study.
Dong L; Zhang L; Hu SY; Feng RM; Zhao XL; Zhang Q; Pan QJ; Zhang X; Qiao YL; Zhao FH
Clin Epigenetics; 2020 May; 12(1):62. PubMed ID: 32381054
[TBL] [Abstract][Full Text] [Related]
16. HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
Wang Q; Song R; Zhao C; Liu H; Yang Y; Gu S; Feng D; He J
Int J Cancer; 2019 Apr; 144(7):1619-1632. PubMed ID: 30230542
[TBL] [Abstract][Full Text] [Related]
17. The Autophagy Process in Cervical Carcinogenesis: Role of Non-Coding-RNAs, Molecular Mechanisms, and Therapeutic Targets.
Lagunas-Martínez A; Madrid-Marina V; Gómez-Cerón C; Deas J; Peralta-Zaragoza O
Cells; 2022 Apr; 11(8):. PubMed ID: 35456001
[TBL] [Abstract][Full Text] [Related]
18. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human papillomavirus type 16 E5 oncoprotein: A promising step in fostering the treatment of cervical cancer.
Hemmat N; Doustvandi MA; Asadzadeh Z; Mokhtarzadeh A; Baradaran B; Baghi HB
Oncol Res; 2021; 29(2):141-148. PubMed ID: 37305401
[TBL] [Abstract][Full Text] [Related]
20. 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression.
Morel A; Baguet A; Perrard J; Demeret C; Jacquin E; Guenat D; Mougin C; Prétet JL
Oncotarget; 2017 Jul; 8(28):46163-46176. PubMed ID: 28521287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
